Learn how you can manage and alleviate your current side effects while actively working to prevent a relapse or secondary cancer using evidence-based, non-toxic therapies.
Click the orange button to the right to learn more.
Aromatase Inhibitors (Tamoxifen, anastrozole, exemestane and letrozole ) has been shown to be effective for breast cancer treatment and prevention. Unfortunately, like many chemotherapy regimens, toxicity of aromatase inhibitors can cause side effects.
If you are worried about breast cancer you probably think about BC prevention yet you don’t want to live with the pain and aches common with AI administration.
There are now a number of studies discussed on PeopleBeatingCancer that establish that curcumin can both enhance the anti-cancer action of certain chemotherapies as well as reduce cancer proliferation. The study linked below discusses how “curcumin reverses chemo-resistance and sensitizes cancer cells to chemotherapy and targeted therapy in breast cancer (BC).”
The devil is in the details as the saying goes. I supplement with a form of curcumin that has been shown to be much more bioavailable (absorbable in the blood). I believe using this formula is essential for us cancer patients. I use and recommend Life Extension Super Bio Curcumin.
I am a cancer survivor and cancer coach. If you are interested in learning more about evidence-based, non-toxic BC therapies please scroll down the page, post a question or comment and I will reply to you ASAP.
“Purpose: Tamoxifen (aromatase inhibitor) administered for 5 years at 20 mg/d is effective in breast cancer treatment and prevention, but toxicity has limited its broad use. Biomarker trials showed that 5 mg/d is not inferior to 20 mg/d in decreasing breast cancer proliferation. We hypothesized that a lower dose given for a shorter period could be as effective in preventing recurrence from breast intraepithelial neoplasia but have a lower toxicity than the standard dose.
Patients and methods: We conducted a multicenter randomized trial of tamoxifen, 5 mg/d or placebo administered for 3 years after surgery in women with hormone-sensitive or unknown breast intraepithelial neoplasia, including atypical ductal hyperplasia and lobular or ductal carcinoma in situ. The primary end point was the incidence of invasive breast cancer or ductal carcinoma in situ.
Results: Five hundred women 75 years of age or younger were included. After a median follow-up of 5.1 years (interquartile range, 3.9-6.3 years), there were
which resulted in a 5-year number needed to treat of 22.
Tamoxifen decreased contralateral breast events by 75%. Patient-reported outcomes were not different between arms except for a slight increase in frequency of daily hot flashes with tamoxifen.
There were 12 serious adverse events with tamoxifen and 16 with placebo, including one deep vein thrombosis and one stage I endometrial cancer with tamoxifen and one pulmonary embolism with placebo.
Conclusion: Tamoxifen (aromatase inhibitor) at 5 mg/d for 3 years can halve the recurrence of breast intraepithelial neoplasia with a limited toxicity, which provides a new treatment option in these disorders.